Dynepo works by stimulating production of red blood cells in the same way as M

Dynepo has no or negligible influence on the ability to drive and use machines. in ic

dosages administered in the renal indication are lower than in the cancer indication. in

must be discarded. a

Hypersensitivity to the active substance or to any of the excipients.

dosages administered in the renal indication are lower than in the cancer indication. ic

Dynepo has no or negligible influence on the ability to drive and use machines. ed

Following 5 days storage at below 25oC the pre filled syringes must be discarded. a in

Dynepo has no or negligible influence on the ability to drive and use machines. ic

discussed above may apply to this patient population is unclear, specifically considering that the dosages administered in the renal indication are lower than in the cancer indication.. a in

Following 5 days storage at below 25oC the pre filled syringes must be discarded. lp

Dynepo has no or negligible influence on the ability to drive and use machines. a in

discussed above may apply to this patient population is unclear, specifically considering that the dosages administered in the renal indication are lower than in the cancer indication. a in

Plan should be provided yearly until the start of the three yearly PSUR cycle. ed M

Keep syringes in the outer carton to protect from light.

BEFORE YOU TAKE DYNEPO M

Your doctor will consider what is the best treatment for you during your pregnancy. lp

Following 5 days storage at below 25oC the pre filled syringes must be discarded.

in

During intercurrent respiratory illness (e. g. bronchitis, upper respiratory tract infections) close monitoring of blood glucose concentrations and dose adjustment may be required on an individual ic

If the insulin inhaler is inadvertently exposed to extremely moist conditions during use this usually pr

Octreotide lanreotide may both decrease or increase insulin requirements.

Dysphonia

Inhaled human insulin has a duration of glucose lowering activity comparable to subcutaneously administered fast acting human insulin and longer than fast acting insulin analogues (see Figure 1).

The percentage of patients who achieved a goal of HbA1c 7.0 was comparable between the treatment groups.

ut ra 80

Consecutive inhalation of three 1 mg unit dose blisters causes a significantly higher insulin exposure M

If the insulin inhaler is inadvertently exposed to extremely moist conditions during use this usually uc

f) T he change in pulmonary function and the need for pulmonary function monitoring g) Smoking in relation to induced alteration in pharmacokinetics M

Read package leaflet and instructions for use of the inhaler before use.

EXUBERA is often given in combination with other diabetes treatments. ic

taking EXUBERA.

ed you do not eat enough, or eat food containing less carbohydrate than normal (sugar and substances similar to sugar are called carbohydrates however, artificial sweeteners are NOT carbohydrates), you lose or are unable to consume carbohydrates due to vomiting or diarrhoea,

These injections may be justified even if it is not certain that you have hypoglycaemia.

Not all pack sizes may be marketed.

through your mouth in one breath. in

Forcaltonin may be given as an intravenous infusion (10 IU per kg body weightover 6 hours).

This summary was last updated in 06 2006. lp ina dic Me

The use of calcitonin in combination with bisphosphonates may result in an additive calcium lowering effect. dic

with bone related disorders, including Paget s disease and osteoporosis.

You should tell your doctor if you are taking other calcium lowering drugs, such as bisphosphonates, as the combination of these drugs with FORCALTONIN might cause the amount of calcium in your blood to become too low. lp

Date of issue of Marketing Authorisation valid throughout the European Union ic

disturbances and loss of consciousness (see section 4.4). dic

syndrome (if not excluded by ECG) and in patients with known acquired QT interval prolongation.

These events have not been associated with signs of ocular abnormality (see sections 4.4 and 4.7).